NCT06715683View on ClinicalTrials.gov

A Study to Evaluate Comparative Bioavailability of BMS-986278 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

December 12, 2024

Primary Completion Date

March 16, 2025

Study Completion Date

March 16, 2025

Conditions
Healthy Volunteers
Interventions
DRUG

BMS-986278 Batched method, Dose A

Specified dose on specified days

DRUG

BMS-986278 Batched method, Dose B

Specified dose on specified days

DRUG

BMS-986278 Continuous method

Specified dose on specified days

Trial Locations (1)

92801

Anaheim Clinical Trials (ACT), Anaheim

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT06715683 - A Study to Evaluate Comparative Bioavailability of BMS-986278 in Healthy Participants | Biotech Hunter | Biotech Hunter